File S1 - Vaccinating Women Previously Exposed to Human Papillomavirus: A Cost-Effectiveness Analysis of the Bivalent Vaccine

Model Description and Supplementary Results.
Table S1, Parameter definitions. Table S2, Number of new partnerships per year stratified by age and risk group. Table S3, Population size and death rates stratified by age group. Table S4, Screening and treatment rates stratified by age group and neoplastic status. Table S5, Lesion specific progression and regression parameters. Table S6, Vaccination Coverage for each dose stratified by age. Table S7, Effect of altering discount rate on median incremental cost effectiveness ratio. Table S8, HPV type specific incidence and transmission probability. Figure S1, A Flow Diagram of the Model. Figure S2, The differential equations of the model. Figure S3, Model estimates of age specific prevalence of HPV-16 compared to trial data to which it was fitted. Figure S4, Cost effectiveness acceptability curves for extending the vaccination catch-up programme up to 24 year olds (assuming a lower coverage of the school based programme targeting 12-13 year olds). Figure S5, Cost effectiveness acceptability curves for extending the vaccination catch-up programme up to 24 year olds (assuming 75% vaccine efficacy for non-naive women). Figure S6, Cost effectiveness acceptability curves for extending the vaccination catch-up programme up to 24 year olds (assuming 50% vaccine efficacy for non-naive women).
(DOC)

模型描述与补充结果。
表S1：参数定义。
表S2：按年龄与风险组别分层的年度新增性伴侣数量。
表S3：按年龄组分层的人口规模与死亡率。
表S4：按年龄组与肿瘤状态分层的筛查与治疗率。
表S5：病灶特异性进展与消退参数。
表S6：按年龄分层的各剂次疫苗接种覆盖率。
表S7：贴现率调整对增量成本效果比中位数的影响。
表S8：人类乳头瘤病毒（Human Papillomavirus，HPV）型别特异性发病率与传播概率。
图S1：模型流程图。
图S2：模型的微分方程组。
图S3：HPV-16年龄特异性感染率的模型估计值与拟合该模型所用试验数据的对比。
图S4：将疫苗补种项目扩展至24岁人群的成本效果可接受性曲线（假设针对12-13岁人群的学校接种项目覆盖率较低）。
图S5：将疫苗补种项目扩展至24岁人群的成本效果可接受性曲线（假设非HPV初免女性的疫苗效力为75%）。
图S6：将疫苗补种项目扩展至24岁人群的成本效果可接受性曲线（假设非HPV初免女性的疫苗效力为50%）。
（DOC文档）